Clinical Trials Logo

Clinical Trial Summary

The primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target organ damage (left ventricular hypertrophy, large arterial stiffness and microalbuminuria). Improvement was defined as the relevant parameter back to normal or declined at least 20%.

The secondary objectives include: blood pressure lowering effect, target organ damage parameters improvement, and the incidence rate of all cause death and cardiovascular events (stroke and myocardia infraction).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02893358
Study type Interventional
Source Shanghai Institute of Hypertension
Contact Yan Li, Professor
Phone 021-64370045
Email liyanshcn@yahoo.com
Status Not yet recruiting
Phase Phase 4
Start date November 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02503943 - Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes Phase 4
Recruiting NCT02156024 - The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension Phase 4
Completed NCT02142881 - Treatment of Masked Hypertension Phase 3
Recruiting NCT02663336 - Prevalence of Masked Hypertension in Nephrological Patients N/A
Not yet recruiting NCT02804074 - MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement N/A